Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1A | P37288 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | CCR5 | P51681 | 2/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | NPC1L1 | Q9UHC9 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5578558 | 0.84 | TACR1 (0.39) | — | |
| SCHEMBL5579059 | 0.84 | TACR1 (0.42) | — | |
| SCHEMBL5582420 | 0.83 | AVPR1A (0.41) | AVPR1AMEN1KMT2ACCR5ALDH1A1 | |
| SCHEMBL5578877 | 0.82 | MEN1 (0.36) | MEN1KMT2ACCR5ALDH1A1KDM4E | |
| SCHEMBL5578492 | 0.74 | HSD11B1 (0.39) | MEN1KMT2AUSP2ALDH1A1LMNA | |
| SCHEMBL5579248 | 0.72 | AVPR1A (0.53) | AVPR1AMEN1KMT2ACCR5USP2 | |
| SCHEMBL5578601 | 0.69 | AVPR1A (0.43) | AVPR1AMEN1KMT2AUSP2ALDH1A1 | |
| SCHEMBL5578579 | 0.67 | HDAC8 (0.35) | MEN1KMT2A | |
| SCHEMBL5579336 | 0.67 | DRD4 (0.50) | AVPR1A | |
| SCHEMBL5578487 | 0.66 | GRIN2B (0.60) | AVPR1AMEN1KMT2AUSP2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005063745-A9 | NOVEL SPIROINDOLINE OR SPIROISOQUINOLINE COMPOUNDS, METHODS OF USE AND COMPOSITIONS THEREOF | ARENA PHARM INC (US) | 2007-02-01 | — | — | WO | claimed |
| US-20070254903-A1 | Novel Spiroindoline or Spiroisoquinoline Compounds, Methods of Use and Compositions Thereof | ARENA PHARMACEUTICALS, INC. (US) | 2007-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254903-A1 | Novel Spiroindoline or Spiroisoquinoline Compounds, Methods of Use and Compositions Thereof | REN, AVPR2, RECQL | AVPR1A 48/4885MEN1 882/4885KMT2A 1940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.